{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:40:50Z","timestamp":1768531250386,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence Reports"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.dadr.2022.100130","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T12:09:19Z","timestamp":1671192559000},"page":"100130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1629-1175","authenticated-orcid":false,"given":"Harold A.","family":"Pollack","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Paykin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier Andres Rojas","family":"Aguilera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dadr.2022.100130_bib0001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jsat.2018.07.006","article-title":"Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington","volume":"93","author":"Amiri","year":"2018","journal-title":"J. Subst. Abuse Treat."},{"issue":"1","key":"10.1016\/j.dadr.2022.100130_bib0002","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00952990.2019.1620261","article-title":"Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment","volume":"46","author":"Amiri","year":"2020","journal-title":"Am. J. Drug Alcohol Abuse"},{"issue":"1","key":"10.1016\/j.dadr.2022.100130_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M18-3457","article-title":"Access to office-based buprenorphine treatment in areas with high rates of opioid-related mortality: an audit study","volume":"171","author":"Beetham","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.dadr.2022.100130_bib0004","unstructured":"Bouchery, E., Morris, R., Little, J., Examining substance use disorder treatment demand and treatment capacity in a changing health care system: Initial findings report. Washington, DC: U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation, Office of Disability, Aging, and Long-term Care Policy; 2015. https:\/\/aspe.hhs.gov\/reports\/examining-substance-use-disorder-treatment-demand-provider-capacity-changing-health-care-system."},{"key":"10.1016\/j.dadr.2022.100130_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108667","article-title":"Not at all what I had expected': discontinuing treatment with extended-release naltrexone (XR-NTX): a qualitative study","volume":"136","author":"Brenna","year":"2022","journal-title":"J. Subst. Abuse Treat."},{"issue":"Pt A","key":"10.1016\/j.dadr.2022.100130_bib0006","article-title":"Population-based estimates of geographic accessibility of medication for opioid use disorder by substance use disorder treatment facilities from 2014 to 2020","volume":"229","author":"Cantor","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"6","key":"10.1016\/j.dadr.2022.100130_bib0007","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s11606-019-04943-6","article-title":"The role of primary care in improving access to medication-assisted treatment for rural medicaid enrollees with opioid use disorder","volume":"34","author":"Cole","year":"2019","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.dadr.2022.100130_bib0008","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/jrh.12375","article-title":"Rural clients' continuity into follow-up substance use disorder treatment: impacts of travel time, incentives, and alerts","volume":"36","author":"Garnick","year":"2020","journal-title":"J. Rural Health"},{"key":"10.1016\/j.dadr.2022.100130_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtrangeo.2020.102770","article-title":"Estimating a large travel time matrix between zip codes in the united states: a differential sampling approach","volume":"86","author":"Hu","year":"2020","journal-title":"J. Transp. Geogr."},{"issue":"5","key":"10.1016\/j.dadr.2022.100130_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250324","article-title":"Opioid treatment deserts: concept development and application in a US midwestern urban county","volume":"16","author":"Hyder","year":"2021","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.dadr.2022.100130_bib0011","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","article-title":"A controlled trial of buprenorphine treatment for opioid dependence","volume":"267","author":"Johnson","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.dadr.2022.100130_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109081","article-title":"Robustness of estimated access to opioid use disorder treatment providers in rural vs. urban areas of the United States","volume":"228","author":"Kiang","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"10118","key":"10.1016\/j.dadr.2022.100130_bib0013","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.dadr.2022.100130_bib0014","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13011-016-0082-1","article-title":"Access to substance use treatment among young adults who use prescription opioids non-medically","volume":"11","author":"Liebling","year":"2016","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"issue":"3","key":"10.1016\/j.dadr.2022.100130_bib0015","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"issue":"4","key":"10.1016\/j.dadr.2022.100130_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001333.pub3","article-title":"Oral naltrexone maintenance treatment for opioid dependence","author":"Minozzi","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.dadr.2022.100130_bib0017","doi-asserted-by":"crossref","first-page":"90","DOI":"10.7326\/M18-0227","article-title":"Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse","volume":"170","author":"Murphy","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.dadr.2022.100130_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108788","article-title":"Consumer access to buprenorphine and methadone in certified community behavioral health centers: a secret shopper study","volume":"139","author":"Presnall","year":"2022","journal-title":"J. Subst. Abuse Treat."},{"issue":"2","key":"10.1016\/j.dadr.2022.100130_bib0019","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1475-6773.13920","article-title":"Medicaid prevalence and opioid use disorder treatment access disparities","volume":"57","author":"Richards","year":"2022","journal-title":"Health Serv. Res."},{"key":"10.1016\/j.dadr.2022.100130_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/948789","article-title":"Distance traveled and cross-state commuting to\u00a0 opioid treatment programs in the United States","author":"Rosenbaum","year":"2011","journal-title":"J. Environ. Public Health"},{"issue":"1","key":"10.1016\/j.dadr.2022.100130_bib0021","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1080\/08897077.2021.1986882","article-title":"A bridge too far? Distance to waivered physicians and utilization of buprenorphine treatment for opioid use disorder in West Virginia Medicaid","volume":"43","author":"Saloner","year":"2022","journal-title":"Subst. Abuse"},{"key":"10.1016\/j.dadr.2022.100130_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2021.106821","article-title":"Alcohol and drug offenses and suicide risk among men who purchased a handgun in California: a cohort study","volume":"153","author":"Schleimer","year":"2021","journal-title":"Prev. Med."},{"key":"10.1016\/j.dadr.2022.100130_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108389","article-title":"Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS)","volume":"128","author":"Waddell","year":"2021","journal-title":"J. Subst. Abuse Treat."}],"container-title":["Drug and Alcohol Dependence Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724622001056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772724622001056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T12:31:39Z","timestamp":1757421099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772724622001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":23,"alternative-id":["S2772724622001056"],"URL":"https:\/\/doi.org\/10.1016\/j.dadr.2022.100130","relation":{},"ISSN":["2772-7246"],"issn-type":[{"value":"2772-7246","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Critical access medication for opioid use disorder (MOUD) treatment facilities in the continental United States","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dadr.2022.100130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100130"}}